AI Enabled Discovery PsychoGenics combines behavioral neurobiology with AI-driven high-throughput in vivo screening and has recently launched an AI-enabled platform (eCube) to accelerate CNS drug discovery, presenting an opportunity to upsell expanded AI analytics and platform licensing to pharmaceutical partners.

Strategic Partnerships Active collaboration history with Sunovion and Carnegie Mellon signals openness to co-development and joint programs, suggesting sales potential for partnered discovery services, translational biomarkers, and AI-enabled phenotypic screening collaborations.

Neuro Focus Growth Specialization in psychiatric and neurodegenerative disorders, pain and inflammation, spinal cord and TBI aligns with high-need CNS programs; target mid-to-large pharma and biotech with CNS portfolios seeking preclinical speed and behavioral phenotyping capabilities.

Funding Momentum Recent SBIR grant of $3M indicates non-dilutive funding activity and validated interest in PsychoGenics’ AI-enabled phenotypic screening approach, creating an entry point for co-development, grant-backed collaborations, or milestone-driven partnerships.

Scale and Capabilities Mid-sized organization with a robust suite of capabilities including behavioral testing, electrophysiology, transgenic models, and microdialysis, offering cross-sell opportunities to expand service breadth for existing clients and to attract CRO-like engagements from larger players seeking specialized CNS preclinical services.